Is Jazz Pharmaceuticals Stock a Good Investment?
Jazz Pharmaceuticals Investment Advice | JAZZ |
- Examine Jazz Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Jazz Pharmaceuticals' leadership team and their track record. Good management can help Jazz Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Jazz Pharmaceuticals' business and its evolving consumer preferences.
- Compare Jazz Pharmaceuticals' performance and market position to its competitors. Analyze how Jazz Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Jazz Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Jazz Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Jazz Pharmaceuticals PLC stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Jazz Pharmaceuticals PLC is a good investment.
Sell | Buy |
Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Jazz Pharmaceuticals Stock
Researching Jazz Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.8. Some equities with similar Price to Book (P/B) outperform the market in the long run. Jazz Pharmaceuticals PLC has Price/Earnings To Growth (PEG) ratio of 0.92. The entity recorded earning per share (EPS) of 7.06. The firm had not issued any dividends in recent years.
To determine if Jazz Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Jazz Pharmaceuticals' research are outlined below:
| Jazz Pharmaceuticals is unlikely to experience financial distress in the next 2 years | |
| Jazz Pharmaceuticals has a strong financial position based on the latest SEC filings | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: US FDA Grants Approval For Zanidatamab Ziihera Bispecific Antibody For Biliary Tract Cancer |
Jazz Pharmaceuticals Quarterly Liabilities And Stockholders Equity |
|
Jazz Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Jazz Pharmaceuticals PLC. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Jazz Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Jazz Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Jazz Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2010-11-04 | 2010-09-30 | 0.34 | 0.41 | 0.07 | 20 | ||
2009-11-05 | 2009-09-30 | -0.14 | -0.05 | 0.09 | 64 | ||
2010-03-03 | 2009-12-31 | 0.07 | 0.17 | 0.1 | 142 | ||
2010-08-10 | 2010-06-30 | 0.14 | 0.28 | 0.14 | 100 | ||
2014-05-08 | 2014-03-31 | 1.79 | 1.61 | -0.18 | 10 | ||
2020-05-05 | 2020-03-31 | 0.67 | 0.45 | -0.22 | 32 | ||
2008-11-13 | 2008-09-30 | -1.29 | -1.07 | 0.22 | 17 | ||
2007-08-09 | 2007-06-30 | -1.69 | -1.38 | 0.31 | 18 |
Know Jazz Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Jazz Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Jazz Pharmaceuticals PLC backward and forwards among themselves. Jazz Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Jazz Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.4 M | Polaris Capital Management, Llc | 2024-09-30 | 1.3 M | Camber Capital Management Llc | 2024-09-30 | 1.1 M | Franklin Resources Inc | 2024-09-30 | 1.1 M | Geode Capital Management, Llc | 2024-09-30 | 1.1 M | Citadel Advisors Llc | 2024-09-30 | 1.1 M | Renaissance Technologies Corp | 2024-09-30 | 1 M | Swedbank Ab | 2024-09-30 | 1 M | Fmr Inc | 2024-09-30 | 835.9 K | Blackrock Inc | 2024-06-30 | 6.1 M | Vanguard Group Inc | 2024-09-30 | 6.1 M |
Jazz Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 7.42 B.Market Cap |
|
Jazz Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.10 | 0.10 | |
| Return On Capital Employed | 0.06 | 0.06 | |
| Return On Assets | 0.04 | 0.04 | |
| Return On Equity | 0.11 | 0.22 |
Determining Jazz Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Jazz Pharmaceuticals is a good buy. For example, gross profit margin measures Jazz Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Jazz Pharmaceuticals' profitability and make more informed investment decisions.
Jazz Pharmaceuticals' Earnings Breakdown by Geography
Please note, the imprecision that can be found in Jazz Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Jazz Pharmaceuticals PLC. Check Jazz Pharmaceuticals' Beneish M Score to see the likelihood of Jazz Pharmaceuticals' management manipulating its earnings.
Evaluate Jazz Pharmaceuticals' management efficiency
Jazz Pharmaceuticals PLC has return on total asset (ROA) of 0.0462 % which means that it generated a profit of $0.0462 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1209 %, meaning that it created $0.1209 on every $100 dollars invested by stockholders. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Jazz Pharmaceuticals' Return On Tangible Assets are fairly stable compared to the past year. Return On Assets is likely to rise to 0.04 in 2024, whereas Return On Capital Employed is likely to drop 0.06 in 2024. At this time, Jazz Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 8.4 B in 2024, whereas Other Assets are likely to drop slightly above 136.8 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 59.04 | 62.00 | |
| Tangible Book Value Per Share | (54.26) | (51.55) | |
| Enterprise Value Over EBITDA | 9.37 | 8.41 | |
| Price Book Value Ratio | 2.08 | 2.98 | |
| Enterprise Value Multiple | 9.37 | 8.41 | |
| Price Fair Value | 2.08 | 2.98 |
Evaluating the management effectiveness of Jazz Pharmaceuticals allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Jazz Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.573 |
Basic technical analysis of Jazz Stock
As of the 28th of November, Jazz Pharmaceuticals retains the Market Risk Adjusted Performance of 0.1455, risk adjusted performance of 0.0546, and Downside Deviation of 1.88. Jazz Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Jazz Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jazz Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jazz Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jazz Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bruce Cozadd over three weeks ago Disposition of 1000 shares by Bruce Cozadd of Jazz Pharmaceuticals at 110.84 subject to Rule 16b-3 | ||
Patricia Carr over three months ago Disposition of 163 shares by Patricia Carr of Jazz Pharmaceuticals at 108.825 subject to Rule 16b-3 | ||
Kennedy Patrick over six months ago Insider Trading | ||
Rick Winningham over a year ago Acquisition by Rick Winningham of 3075 shares of Jazz Pharmaceuticals subject to Rule 16b-3 | ||
Matthew Young over a year ago Payment of 1348 shares by Matthew Young of Jazz Pharmaceuticals subject to Rule 16b-3 |
Jazz Pharmaceuticals' Outstanding Corporate Bonds
Jazz Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Jazz Pharmaceuticals PLC uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Jazz bonds can be classified according to their maturity, which is the date when Jazz Pharmaceuticals PLC has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Understand Jazz Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Jazz Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0546 | |||
| Market Risk Adjusted Performance | 0.1455 | |||
| Mean Deviation | 1.49 | |||
| Semi Deviation | 1.75 | |||
| Downside Deviation | 1.88 | |||
| Coefficient Of Variation | 1582.17 | |||
| Standard Deviation | 2.04 | |||
| Variance | 4.18 | |||
| Information Ratio | (0.0006) | |||
| Jensen Alpha | 0.0133 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.0007) | |||
| Treynor Ratio | 0.1355 | |||
| Maximum Drawdown | 10.09 | |||
| Value At Risk | (2.77) | |||
| Potential Upside | 3.8 | |||
| Downside Variance | 3.53 | |||
| Semi Variance | 3.08 | |||
| Expected Short fall | (1.57) | |||
| Skewness | 0.5543 | |||
| Kurtosis | 2.06 |
| Risk Adjusted Performance | 0.0546 | |||
| Market Risk Adjusted Performance | 0.1455 | |||
| Mean Deviation | 1.49 | |||
| Semi Deviation | 1.75 | |||
| Downside Deviation | 1.88 | |||
| Coefficient Of Variation | 1582.17 | |||
| Standard Deviation | 2.04 | |||
| Variance | 4.18 | |||
| Information Ratio | (0.0006) | |||
| Jensen Alpha | 0.0133 | |||
| Total Risk Alpha | (0.20) | |||
| Sortino Ratio | (0.0007) | |||
| Treynor Ratio | 0.1355 | |||
| Maximum Drawdown | 10.09 | |||
| Value At Risk | (2.77) | |||
| Potential Upside | 3.8 | |||
| Downside Variance | 3.53 | |||
| Semi Variance | 3.08 | |||
| Expected Short fall | (1.57) | |||
| Skewness | 0.5543 | |||
| Kurtosis | 2.06 |
Consider Jazz Pharmaceuticals' intraday indicators
Jazz Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Jazz Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 6325.93 | |||
| Daily Balance Of Power | (0.05) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 123.26 | |||
| Day Typical Price | 123.05 | |||
| Price Action Indicator | (0.69) | |||
| Period Momentum Indicator | (0.15) | |||
| Relative Strength Index | 75.08 |
Jazz Pharmaceuticals Corporate Filings
8K | 26th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 13th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
Jazz Stock media impact
Far too much social signal, news, headlines, and media speculation about Jazz Pharmaceuticals that are available to investors today. That information is available publicly through Jazz media outlets and privately through word of mouth or via Jazz internal channels. However, regardless of the origin, that massive amount of Jazz data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Jazz Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Jazz Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Jazz Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Jazz Pharmaceuticals alpha.
Jazz Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Jazz Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Jazz Pharmaceuticals PLC Historical Investor Sentiment
Investor biases related to Jazz Pharmaceuticals' public news can be used to forecast risks associated with an investment in Jazz. The trend in average sentiment can be used to explain how an investor holding Jazz can time the market purely based on public headlines and social activities around Jazz Pharmaceuticals PLC. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Jazz Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Jazz Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Jazz Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Jazz Pharmaceuticals.
Jazz Pharmaceuticals Corporate Management
| Finbar Larkin | VP Operations | Profile | |
| George Eliades | Senior Officer | Profile | |
| Daniel Swisher | NonExecutive Employee | Profile | |
| Patricia Carr | Senior Officer | Profile | |
| Jed MD | Senior Medicine | Profile | |
| Andrea Flynn | VP Relations | Profile |
Additional Tools for Jazz Stock Analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.